RPTX News and Press, Repare Therapeutics Inc.

Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...

Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...

2024-06-04 16:28:44 ET More on Repare Therapeutics Repare Therapeutics appoints Steven Stein to its board of directors Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for t...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare C...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced s...

2024-05-08 09:17:03 ET A %Biotech company is turning heads so far during Wednesday’s premarket hours following the company reporting higher than expected revenue and EPS. According to a handful of releases, the company’s EPS of $0.30 beat estimates by a staggering $0.32, a...

2024-05-07 17:49:11 ET More on Repare Therapeutics Repare Therapeutics appoints Steven Stein to its board of directors Repare to regain global rights to camonsertib from Roche Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data...

Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination...